Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2019 Jun 12;25(10):2024–2030. doi: 10.1016/j.bbmt.2019.06.004

Table 3b.

Incidence of pulmonary toxicity

Outcomes N eval Prob (95% CI) N eval Prob (95% CI) N eval Prob
(95% CI)
N eval Prob
(95% CI)
N eval Prob
(95% CI)
p-value
Less than 1 (N = 623) 1 year (N = 382) 2-4 years (N = 816) 5-9 years (N = 1183) 10-20 years (N = 2018)
Pneumonitis 612 364 785 1158 1964
   100-day 8 (6-10)% 6 (4-9)% 4 (3-5)% 4 (3-5)% 6 (5-7)% 0.04
   6 months 8 (6-10)% 7 (5-10)% 6 (4-7)% 5 (4-6)% 7 (6-8)%
   1-year 9 (7-12)% 9 (6-12)% 6 (5-8)% 6 (5-8)% 8 (7-9)%
Diffuse alveolar hemorrhage 613 364 786 1159 1964
   100-day 4 (3-6)% 2 (1-4)% 1 (1-2)% 1 (0-2)% 2 (1-2)% 0.001
   6 months 4 (3-6)% 2 (1-4)% 2 (1-3)% 1 (1-2)% 2 (1-3)%
   1-year 5 (3-7)% 3 (1-5)% 2 (1-3)% 1 (1-2)% 2 (2-3)%
Pulmonary GVHD 617 379 808 1171 1957
   100-day 0 (0-1)% 0 (0-1)% 0 (0-0)% 1 (0-1)% 1 (0-1)% <0.001
   6 months 1 (0-1)% 1 (0-3)% 1 (0-1)% 2 (1-3)% 2 (1-2)%
   1-year 1 (0-2)% 2 (1-4)% 1 (0-2)% 2 (2-3)% 3 (2-4)%

DAH, diffuse alveolar hemorrhage; GVHD, graft-versus-host disease.